{
    "nctId": "NCT00050427",
    "briefTitle": "A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Neoplasms, Neoplasms by Site, Breast Diseases, Skin Diseases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 53,
    "primaryOutcomeMeasure": "Number of patients with objective response in each treatment arm.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of advanced breast cancer\n* Prior therapy with anthracycline and taxane (2 types of chemotherapy drugs)\n* At least one measureable tumor lesion\n* Adequate bone marrow, hepatic and renal function\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\nExclusion Criteria:\n\n* Known hypersensitivity to any components of the i.v. formulation of ET-743 or dexamethasone\n* Pregnant or lactating women\n* Known metastases (spread) of cancer to the central nervous system\n* History of another neoplastic disease unless in remission for five years or more.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}